Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbinoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.81 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.81 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.81 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.81 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbinoxamine SCHEMBL4223043 | 1.00 | POLB (1.00) | POLBLMNACHRM2SLC6A2SLC6A4 | |
| Rotoxamine SCHEMBL28665889 | 1.00 | POLB (1.00) | POLBLMNACHRM2SLC6A2SLC6A4 | |
| Carbinoxamine SCHEMBL97704 | 1.00 | POLB (1.00) | POLBLMNACHRM2SLC6A2SLC6A4 | |
| Carbinoxamine SCHEMBL97703 | 1.00 | POLB (1.00) | POLBLMNACHRM2SLC6A2SLC6A4 | |
| Rotoxamine SCHEMBL6312191 | 0.90 | CHRM2 (0.83) | POLBLMNACHRM2SLC6A2SLC6A4 | |
| Carbinoxamine SCHEMBL29414093 | 0.90 | CHRM2 (1.00) | POLBLMNACHRM2SLC6A2SLC6A4 | |
| Carbinoxamine SCHEMBL29881788 | 0.90 | CHRM2 (1.00) | POLBLMNACHRM2SLC6A2SLC6A4 | |
| Carbinoxamine SCHEMBL5070 | 0.90 | CHRM2 (1.00) | POLBLMNACHRM2SLC6A2SLC6A4 | |
| Rotoxamine SCHEMBL29485023 | 0.90 | CHRM2 (1.00) | POLBLMNACHRM2SLC6A2SLC6A4 | |
| Rotoxamine SCHEMBL141389 | 0.90 | CHRM2 (1.00) | POLBLMNACHRM2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028324-A1 | MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-02-08 | — | — | WO | claimed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250169516-A1 | METHODS, DEVICES AND COMPOSITIONS FOR PRESERVING HUMAN MILK | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250144067-A1 | PERSONALIZED STARVATION THERAPY FOR CANCER | FAETH THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-12239142-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240268402-A1 | Methods, Devices and Compositions for Preserving Human Milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240156920-A1 | COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME | STANDARD OF CARE CORPORATION | 2024-05-16 | — | — | US | disclosed |
| WO-2024028324-A1 | MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-02-08 | — | — | WO | disclosed |
| WO-2022153045-A1 | METHODS AND COMPOSITIONS FOR ANTIBIOTIC POTENTIATION | Quadram Institute Bioscience (GB) | 2022-07-21 | — | — | WO | disclosed |
| EP-4017524-A1 | COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME | Standard of Care Corporation (US) | 2022-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156920-A1 | COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME | MMP1, MMP2, MMP8 | HRH1 686/4885POLB 1143/4885LMNA 3136/4885 |
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | LPL, CEL, LPO | HRH1 4092/4885POLB 1376/4885LMNA 164/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | HRH1 2817/4885POLB 4628/4885LMNA 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.